Trials / Completed
CompletedNCT07161011
Phase 2b Controlled Study of Dosing Techniques - Part B
Phase 2b, Proof-of-Concept, Single-center, Double-Masked, Randomized Study Comparing the Safety, Tolerability, and Efficacy of Three Different Ophthalmic Eyelid Wipe Dosing Techniques Using IVW-1001 in Subjects With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- IVIEW Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Double-masked, dose-response of two concentrations of IVW-1001
Detailed description
Using the best dosing technique from Study NCT07140380, subjects will be randomized to one of two concentrations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IVW-1001 Ophthalmic Eyelid Wipe 0.2% | Low dose |
| DRUG | IVW-1001 Ophthalmic Eyelid Wipe 0.4% | High dose |
Timeline
- Start date
- 2025-09-08
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
- First posted
- 2025-09-08
- Last updated
- 2026-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07161011. Inclusion in this directory is not an endorsement.